Outlook Therapeutics Inc (OTLK)
7.58
-0.15
(-1.94%)
USD |
NASDAQ |
May 10, 16:00
7.58
0.00 (0.00%)
After-Hours: 20:00
Outlook Therapeutics Cash from Operations (Quarterly): -13.03M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -13.03M |
| September 30, 2023 | -12.74M |
| June 30, 2023 | -13.22M |
| March 31, 2023 | -8.115M |
| December 31, 2022 | -8.901M |
| September 30, 2022 | -10.25M |
| June 30, 2022 | -21.10M |
| March 31, 2022 | -14.33M |
| December 31, 2021 | -10.99M |
| September 30, 2021 | -8.990M |
| June 30, 2021 | -20.19M |
| March 31, 2021 | -11.75M |
| December 31, 2020 | -13.32M |
| September 30, 2020 | -12.08M |
| June 30, 2020 | -5.956M |
| March 31, 2020 | -7.083M |
| December 31, 2019 | -6.674M |
| September 30, 2019 | -5.942M |
| June 30, 2019 | -10.31M |
| Date | Value |
|---|---|
| March 31, 2019 | -6.259M |
| December 31, 2018 | -9.781M |
| September 30, 2018 | -8.394M |
| June 30, 2018 | -8.535M |
| March 31, 2018 | -7.439M |
| December 31, 2017 | -8.671M |
| September 30, 2017 | 0.0799M |
| June 30, 2017 | -5.633M |
| March 31, 2017 | -4.110M |
| December 31, 2016 | -5.842M |
| September 30, 2016 | -10.37M |
| June 30, 2016 | -16.04M |
| March 31, 2016 | -7.058M |
| December 31, 2015 | -12.01M |
| September 30, 2015 | -11.01M |
| June 30, 2015 | -10.04M |
| March 31, 2015 | -2.760M |
| December 31, 2014 | -3.666M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-21.10M
Minimum
Jun 2022
-5.942M
Maximum
Sep 2019
-11.31M
Average
-10.99M
Median
Dec 2021
Cash from Operations (Quarterly) Benchmarks
| Cutera Inc | -33.77M |
| Actinium Pharmaceuticals Inc | -7.374M |
| GT Biopharma Inc | -2.047M |
| Karyopharm Therapeutics Inc | -18.58M |
| Marinus Pharmaceuticals Inc | -26.99M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | -0.0032M |
| Free Cash Flow | -47.10M |
| Free Cash Flow Per Share (Quarterly) | -1.002 |
| Free Cash Flow Yield | -48.09% |